Sign In
Buy DXCM
$83.45
+8.91 (+11.95%)
At Close: Jul 31, 2026
DexCom Stock Up on Q2 Earnings & Revenue Beat, Margins Rise
02:42pm, Friday, 31'st Jul 2026
DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.
DexCom Inc (DXCM) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Signal Robust Momentum
12:04am, Friday, 31'st Jul 2026
Revenue: Worldwide revenue of $1.31 billion, up 13% reported and 12% organic year-over-year.US Revenue: $933 million, up 11% year-over-year.International Revenu
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
10:03pm, Thursday, 30'th Jul 2026
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
DexCom Q2 Earnings Call Highlights
07:04pm, Thursday, 30'th Jul 2026
DexCom NASDAQ: DXCM reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
06:26pm, Thursday, 30'th Jul 2026
DexCom (DXCM) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.48 per share a year ago.
Dexcom raises annual revenue forecast on strong demand for glucose monitors
04:32pm, Thursday, 30'th Jul 2026
Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on Thursday, banking on sustained demand for its continuous glucose monitors that track blood sugar
Dexcom Reports Second Quarter 2026 Financial Results
04:02pm, Thursday, 30'th Jul 2026
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold
04:34pm, Wednesday, 29'th Jul 2026
They may profit from the rapidly growing GLP-1 market in very different ways.
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
11:56am, Wednesday, 29'th Jul 2026
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
09:12am, Wednesday, 29'th Jul 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
Dimensional Fund Advisors LP Buys 23,844 Shares of DexCom, Inc. $DXCM
03:39am, Wednesday, 29'th Jul 2026
Dimensional Fund Advisors LP boosted its stake in DexCom, Inc. (NASDAQ: DXCM) by 1.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Comm
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 28'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion
10:06am, Monday, 27'th Jul 2026
DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
11:01am, Thursday, 23'rd Jul 2026
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors
